FDA Adds Boxed Warning for Symptomatic Hypophosphatemia With Ferric Carboxymaltose

What the boxed warning changes

The FDA’s September 2026 action moves hypophosphatemia into the most prominent safety section of ferric carboxymaltose labeling. The practical change is not that phosphate depletion has newly appeared, but that it now warrants greater weight when clinicians choose an intravenous iron product, evaluate symptoms after treatment or consider another course.

Ferric carboxymaltose can cause renal phosphate wasting through an increase in biologically active fibroblast growth factor 23, or FGF23. This lowers renal phosphate reabsorption and can suppress active vitamin D, contributing to secondary hyperparathyroidism and prolonged phosphate loss. Severe or persistent cases may cause muscle weakness, bone pain, fractures, osteomalacia, altered mental status, respiratory compromise or cardiac complications.

Recognition can be difficult because early manifestations—including fatigue, weakness and reduced exercise tolerance—overlap with iron deficiency and the conditions that prompted intravenous iron treatment. A patient whose fatigue persists or worsens after iron repletion therefore may require reassessment rather than an assumption that the iron deficiency remains inadequately treated.

The warning also makes repeat exposure more consequential. Clinicians considering another course should account for previous ferric carboxymaltose treatment, the interval since treatment, unresolved symptoms and any available phosphate results. A normal phosphate concentration before the first infusion does not eliminate the possibility of a clinically important decline afterward.

Comparative evidence behind the concern

A randomized, double-blind trial compared ferric carboxymaltose with ferumoxytol in 1,997 adults with iron-deficiency anemia who could not tolerate oral iron or had an unsatisfactory response. Participants were followed for five weeks. Hypophosphatemia was substantially more frequent with ferric carboxymaltose, and nearly three in 10 recipients still had a low phosphate concentration at the end of follow-up.

The same trial included a physiological substudy that documented increases in intact FGF23, urinary phosphate excretion and parathyroid hormone after ferric carboxymaltose, alongside reductions in serum phosphate and active vitamin D. The randomized comparison and mechanistic measurements support a drug-related effect rather than a simple association with the underlying iron deficiency.

Two randomized clinical trials published in JAMA also compared ferric carboxymaltose with iron isomaltoside, now called ferric derisomaltose, among adults with iron-deficiency anemia. Across the two trials, hypophosphatemia occurred in approximately three-quarters of ferric carboxymaltose recipients, compared with about 8% of those receiving the alternative preparation. These trials reinforce that the risk is not uniform across intravenous iron formulations.

Incidence estimates vary with the phosphate threshold, treatment regimen, patient population and timing of laboratory testing. The high rates in actively monitored trials should not be interpreted as the expected frequency of symptomatic disease in every practice setting. They do, however, show that biochemical hypophosphatemia can be common and may remain undetected without planned testing.

Translating the warning into risk assessment

Risk assessment begins before administration. Factors that can increase concern include preexisting hypophosphatemia, repeated or closely spaced ferric carboxymaltose courses, vitamin D deficiency, malnutrition, hyperparathyroidism and gastrointestinal disorders associated with impaired phosphate or vitamin absorption. Medications or conditions affecting proximal renal tubular function may also increase susceptibility.

The evidence supports checking serum phosphate before treatment when a patient is already at risk or when repeat exposure is being considered. Preexisting hypophosphatemia should be addressed before ferric carboxymaltose is given. The current FDA-approved labeling and boxed-warning language should determine the required monitoring steps; trial schedules can inform clinical judgment but do not replace the label.

After treatment, testing is most relevant for patients with risk factors, new compatible symptoms or a likely need for another course. Trial data show that phosphate may continue to fall after the infusion rather than immediately, with prominent abnormalities during the first several weeks. Monitoring limited to the infusion visit can therefore miss the clinically relevant period.

An abnormally low result should prompt assessment of severity, symptoms and persistence. Evaluation may include repeat serum phosphate and, when clinically appropriate, calcium, magnesium, renal function, parathyroid hormone and vitamin D status. Urinary phosphate measurements can help establish renal phosphate wasting in complex or persistent cases. Management should follow the updated label and the clinical severity; severe symptoms may require urgent evaluation.

Choice of intravenous iron also enters the discussion. The comparative trials show that hypophosphatemia risk differs by formulation, so susceptibility and anticipated need for repeated treatment can reasonably influence product selection. That does not establish one preparation as preferable for every patient: iron requirement, indication, infusion burden, prior response, hypersensitivity risk, access and payer policy remain relevant.

Important evidence gaps

The principal comparative trials were designed around biochemical hypophosphatemia and short-term physiological effects. They were not powered to quantify uncommon outcomes such as osteomalacia, fracture, arrhythmia or hospitalization, and follow-up was too short to define recovery after recurrent exposure over months or years.

Trial incidence may not generalize directly to every patient receiving ferric carboxymaltose because laboratory schedules detect asymptomatic events that routine care may miss. Conversely, passive safety reporting can underestimate events when fatigue or weakness is attributed to anemia. Evidence is also limited on the most effective testing schedule and the phosphate threshold at which asymptomatic patients benefit from intervention.

The boxed warning appropriately increases visibility, but it does not replace clinical interpretation. The bedside task is to connect exposure, timing, symptoms and laboratory findings while avoiding both underrecognition of severe depletion and overinterpretation of a single mild result.

Questions clinicians ask

Who is most likely to need phosphate testing?

Testing is most relevant for patients with preexisting low phosphate, vitamin D deficiency, malnutrition, hyperparathyroidism, malabsorptive gastrointestinal disease, possible renal phosphate wasting or repeated ferric carboxymaltose exposure. New weakness, bone pain, confusion or worsening fatigue after treatment also lowers the threshold for checking phosphate.

When can hypophosphatemia appear after an infusion?

The decline may develop over days and become most apparent during the first several weeks after treatment. Because the randomized evidence found persistent hypophosphatemia at five weeks in some ferric carboxymaltose recipients, a normal value at the infusion visit does not rule out a later abnormality.

Does every low phosphate result require emergency treatment?

No. Clinical urgency depends on the phosphate concentration, symptoms, trajectory and comorbidities. Severe weakness, neurological changes, respiratory symptoms or cardiac concerns warrant prompt assessment, while an asymptomatic mild reduction may be managed with repeat testing and evaluation of contributing factors under the updated label.

Should ferric carboxymaltose be avoided after a previous episode?

A previous episode should materially change the risk-benefit assessment, especially if it was severe, symptomatic or prolonged. Comparative trials show that other intravenous iron formulations have lower biochemical hypophosphatemia rates, but selection should still incorporate the indication, treatment history, formulation-specific risks, availability and FDA-approved labeling.

References

1. FDA Adds Boxed Warning for Ferric Carboxymaltose Injection — U.S. Food and Drug Administration, 2026 2. Randomized Trial of Intravenous Iron-Induced Hypophosphatemia — JCI Insight, 2018 3. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials — JAMA, 2020